Jump to content

José-Alain Sahel

From Wikipedia, the free encyclopedia
José-Alain Sahel
Born
Algeria
NationalityFrench
Alma materUniversity of Strasburg
AwardsThe Legion of Honour (2008); National Order of Merit (2002); Wolf Prize in Medicine (2024)
Scientific career
FieldsOphthalmology
InstitutionsThe Vision Institute, Paris

José-Alain Sahel is a French ophthalmologist and scientist. He is currently the chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine, director of the UPMC Vision Institute, and the Eye and Ear Foundation Chair of Ophthalmology. Dr. Sahel previously led the Vision Institute (French: Institut de la Vision) in Paris, a research center associated with one of the oldest eye hospitals of Europe - Quinze-Vingts National Eye Hospital in Paris, founded in 1260. He is a pioneer in the field of artificial retina and eye regenerative therapies.[1] He is a member of the French Academy of Sciences.

Biography

[edit]

José-Alain Sahel was born in Tlemcen (Algeria) in 1955. He graduated from the Medical Faculty of the Medical School of Paris University (1980) He followed with a residency in ophthalmology at the Adolphe de Rothschild Ophthalmology Foundation in Paris and the Louis Pasteur University Hospital, Strasbourg, France (1980-1984) and started a fellowship at the same institution (1984-1986).He spent his first 20 professional years in the University Hospital of Strasbourg working as ophthalmologist and after moved to Quinze-Vingts National Eye Hospital in Paris, where he became department head in 2001. At the same period he held a position of the Chief of Ophthalmology and Pathology Service at Adolphe de Rothschild Foundation.

José-Alain Sahel also held the chair of the Professor of Ophthalmology at the University Pierre and Marie Curie in Paris and the Professor of Biomedical Sciences (Cumberlege Chair) at University College London.[2] He performed a research fellowship at Massachusetts Eye and Ear Infirmary, Harvard Medical School with Professor Daniel. M. Albert and a visiting scholarship at Harvard Biological Laboratories with Professor John. E. Dowling.[citation needed][3]

In October 2016, José-Alain Sahel was hired by the University of Pittsburgh School of Medicine as chair of the Department of Ophthalmology, the director of the UPMC Vision Institute, and the Eye and Ear Foundation Chair of Ophthalmology.[4]

Research

[edit]

José-Alain Sahel has contributed to advancements in basic and clinical research in the field of the vision. In 1992 he founded the Laboratory of Cellular and Molecular Physiopathology of the Retina in Strasbourg that specialized in translational research on the mechanisms of retinal cell degeneration.

Later this laboratory became the heart of the Vision Institute that José-Alain Sahel founded in Paris in 2008.[5] This institute is one of the largest centres of integrated research on eye diseases in Europe and combines fifteen academic and clinical teams employing more than 250 researchers. There he continued his research on developmental biology, functional genomics, physiology and therapeutics (stem cells, gene therapy, pharmacology, artificial retina), research on relevant biomarkers and disease models. The common thread of his work is understanding and prevention of central vision loss through degeneration of photoreceptor cells (retinitis pigmentosa genetic) and age-related degeneration (AMD).

One of the major discoveries made by José-Alain Sahel and his colleagues Thierry Léveillard and Saddek Mohand-Said is that the rod photoreceptors produce a trophic factor (called sustainability factor cones or RdCVF for Rod-derived Cone Viability Factor) which uses the cone photoreceptors to survive.[6] This discovery provided the biological basis for paracrine interactions between rods and cones showing that these interactions play a key role in maintaining the viability of photoreceptor cells. RdCVF through these factor could preserve central vision in some blinding human diseases.

Clinical research led by José-Alain Sahel is closely entangled with the experimental research: information processing, genetic, therapeutic research, including modelling, evidence of pre-clinical concepts, technological developments in imaging and surgery, forming an integrated site research on diseases of vision. Conducted clinical research include the first clinical gene therapy trials (Stargardt) with a North American center and integrated clinical[clarification needed] of French National Reference Center on Retinal dystrophies with participation of more than 5000 patients. José-Alain Sahel coordinates large-scale European research programs on the retina, functional genomics, retinal neuroprotection, aging, and more recently on theraputicd[clarification needed]. José-Alain Sahel is also a coordinator of a network of over 80 centres of excellence in clinical trials of retinal diseases among Europeans.

Research of José-Alain Sahel is also focused on the search for new therapeutic strategies to regain sight of visually impaired and blind people. He is one of the pioneers (with the Study Group on the retinal implant Argus II) in the Research on visual prostheses that could potentially become a breakthrough therapy for visually disabled patients, and allow them to regain some autonomy with recognition of objects or words, orientation and mobility. The results obtained and published as part of an international multicentre trial on retinal prostheses have resulted in FDA authorisation.[citation needed]

With the research team of Botond Roska at the Friedrich Miescher from Institute for Biomedical Research in Basel, Switzerland, the research group of José-Alain Sahel and Serge Picaud was among the first transforme[clarification needed] through optogenetics cells an artificial retina retinal photoreceptors connected to circuit and to use gene therapy to restore vision. They also succeeded in showing that patients receiving this therapy is applicable can be identified and selected by non-invasive methods retinal imaging in high resolution, allowing to quickly benefit these patients discoveries from the laboratory. New high-resolution retinal imaging tools are also developed by José-Alain Sahel and his colleagues (optical coherence tomography, adaptive optics with Michel Paques), to refine the characterization of functional deficits and dispose of specific therapeutic efficacy and reproductibles markers.

Currently, José-Alain Sahel is a member of the Scientific Advisory Board of several public and private institutions : Faculty of Medicine Pierre and Marie Curie, Foundation Fighting Blindness, Steering Committee of the European Vision Institute (EVI EEIG), Chairman of the Steering Committee of European Vision Institute - Clinical Trials - Sites of excellence (EVI- CR), City of Paris. He serves on several editorial boards of prestigious journals such as the Journal of Clinical Investigation, Science Translational Medicine, JAMA - Ophthalmology, Progress in retinal and Eye Research .

Companies created

[edit]
  • Fovéa Pharmaceuticals (created in 2005, acquired by Sanofi Aventis)
  • StreetLab (created in 2011) a company dedicated to the evaluation and development of new products to improve the autonomy and quality of life of visually impaired.
  • GenSight Biologics (founded in 2012 dedicated to the development of treatments for degenerative diseases of the retina based on the use of gene therapy)
  • Pixium (founded in 2012 Pixium developing a new generation of artificial retina designed to be implanted in the eye of patients who have lost their sight)

Selected publications

[edit]

References

[edit]
  1. ^ José-Alain Sahel, master of vision (Report). CNRS. 2012. p. 23. Retrieved 2018-04-11.
  2. ^ "University College London profile for José-Alain Sahel". iris.ucl.ac.uk. University College London. Archived from the original on 2016-03-04. Retrieved 2018-02-08.
  3. ^ Vitone, Elaine (2016). ""Into a World of Light"". Pitt Med Magazine. Cited work between Sahel and Dowling.{{cite news}}: CS1 maint: date and year (link)
  4. ^ "Quest to Cure Blindness: Pitt, UPMC Recruit World-Renowned Expert in Research and Therapies for Blindness and Vision Impairment". University of Pittsburgh Medical Center. 2016-10-05. Retrieved 2018-04-11.
  5. ^ Petitnicolas, Catherine (2008-03-25). "Le premier centre européen de la vision créé à Paris". FIGARO (in French). Retrieved 2018-04-11.
  6. ^ Sahel, JA. (2010). "Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling". Sci Transl Med. 2 (26): 26ps16. doi:10.1126/scitranslmed.3000866. PMC 2896730. PMID 20375363.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=José-Alain_Sahel&oldid=1253723342"